SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population

Yi Wei Yeh, Cheng Jueng Chen, Fong Lin Jang, Shin Chang Kuo, Chun Yen Chen, Chih Sung Liang, Pei Shen Ho, Che Hung Yen, Jia Fwu Shyu, Fang Jung Wan, Ru-Band Lu, San Yuan Huang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: Venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) type, is used to treat patients with major depressive disorder (MDD). Much evidence suggests that genetic polymorphisms may modulate serotonergic and noradrenergic function, thereby affecting the treatment efficacy of venlafaxine. The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. Method: An 8-week naturalistic treatment study with venlafaxine was carried out in 243 Han Chinese patients with MDD. The patients were screened for seven single-nucleotide polymorphisms of the SLC6A2 gene. Of the enrolled patients, 161 completed the 8-week treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was used to assess the improvement of depressive symptoms in each subject from baseline to the endpoint. For better presentation of time-course change of remission status, a Cox regression analysis for remission incidence during the 8-week treatment was conducted. Results: Between remitters and non-remitters, significant differences in genotype frequencies were observed in five of the investigated SLC6A2 variants (rs28386840, rs1532701, rs40434, rs13333066, rs187714). GCG haplotype (rs40434-rs13333066-rs187714) in the SLC6A2 gene showed a association with non-remission. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714). Conclusion: Our results suggest that the variation of the SLC6A2 gene is associated with treatment remission after venlafaxine in patients with MDD.

Original languageEnglish
Pages (from-to)33-39
Number of pages7
JournalJournal of Psychiatric Research
Volume61
DOIs
Publication statusPublished - 2015 Feb 1

Fingerprint

Major Depressive Disorder
Depression
Population
Genes
Therapeutics
Regression Analysis
Norepinephrine Plasma Membrane Transport Proteins
Incidence
Genetic Polymorphisms
Haplotypes
Antidepressive Agents
Single Nucleotide Polymorphism
Venlafaxine Hydrochloride
Genotype

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Yeh, Yi Wei ; Chen, Cheng Jueng ; Jang, Fong Lin ; Kuo, Shin Chang ; Chen, Chun Yen ; Liang, Chih Sung ; Ho, Pei Shen ; Yen, Che Hung ; Shyu, Jia Fwu ; Wan, Fang Jung ; Lu, Ru-Band ; Huang, San Yuan. / SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population. In: Journal of Psychiatric Research. 2015 ; Vol. 61. pp. 33-39.
@article{dc3f61b9304a4a13a1a4a6a0f97bb2ff,
title = "SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population",
abstract = "Objective: Venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) type, is used to treat patients with major depressive disorder (MDD). Much evidence suggests that genetic polymorphisms may modulate serotonergic and noradrenergic function, thereby affecting the treatment efficacy of venlafaxine. The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. Method: An 8-week naturalistic treatment study with venlafaxine was carried out in 243 Han Chinese patients with MDD. The patients were screened for seven single-nucleotide polymorphisms of the SLC6A2 gene. Of the enrolled patients, 161 completed the 8-week treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was used to assess the improvement of depressive symptoms in each subject from baseline to the endpoint. For better presentation of time-course change of remission status, a Cox regression analysis for remission incidence during the 8-week treatment was conducted. Results: Between remitters and non-remitters, significant differences in genotype frequencies were observed in five of the investigated SLC6A2 variants (rs28386840, rs1532701, rs40434, rs13333066, rs187714). GCG haplotype (rs40434-rs13333066-rs187714) in the SLC6A2 gene showed a association with non-remission. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714). Conclusion: Our results suggest that the variation of the SLC6A2 gene is associated with treatment remission after venlafaxine in patients with MDD.",
author = "Yeh, {Yi Wei} and Chen, {Cheng Jueng} and Jang, {Fong Lin} and Kuo, {Shin Chang} and Chen, {Chun Yen} and Liang, {Chih Sung} and Ho, {Pei Shen} and Yen, {Che Hung} and Shyu, {Jia Fwu} and Wan, {Fang Jung} and Ru-Band Lu and Huang, {San Yuan}",
year = "2015",
month = "2",
day = "1",
doi = "10.1016/j.jpsychires.2014.11.017",
language = "English",
volume = "61",
pages = "33--39",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Elsevier Limited",

}

Yeh, YW, Chen, CJ, Jang, FL, Kuo, SC, Chen, CY, Liang, CS, Ho, PS, Yen, CH, Shyu, JF, Wan, FJ, Lu, R-B & Huang, SY 2015, 'SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population', Journal of Psychiatric Research, vol. 61, pp. 33-39. https://doi.org/10.1016/j.jpsychires.2014.11.017

SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population. / Yeh, Yi Wei; Chen, Cheng Jueng; Jang, Fong Lin; Kuo, Shin Chang; Chen, Chun Yen; Liang, Chih Sung; Ho, Pei Shen; Yen, Che Hung; Shyu, Jia Fwu; Wan, Fang Jung; Lu, Ru-Band; Huang, San Yuan.

In: Journal of Psychiatric Research, Vol. 61, 01.02.2015, p. 33-39.

Research output: Contribution to journalArticle

TY - JOUR

T1 - SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population

AU - Yeh, Yi Wei

AU - Chen, Cheng Jueng

AU - Jang, Fong Lin

AU - Kuo, Shin Chang

AU - Chen, Chun Yen

AU - Liang, Chih Sung

AU - Ho, Pei Shen

AU - Yen, Che Hung

AU - Shyu, Jia Fwu

AU - Wan, Fang Jung

AU - Lu, Ru-Band

AU - Huang, San Yuan

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Objective: Venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) type, is used to treat patients with major depressive disorder (MDD). Much evidence suggests that genetic polymorphisms may modulate serotonergic and noradrenergic function, thereby affecting the treatment efficacy of venlafaxine. The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. Method: An 8-week naturalistic treatment study with venlafaxine was carried out in 243 Han Chinese patients with MDD. The patients were screened for seven single-nucleotide polymorphisms of the SLC6A2 gene. Of the enrolled patients, 161 completed the 8-week treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was used to assess the improvement of depressive symptoms in each subject from baseline to the endpoint. For better presentation of time-course change of remission status, a Cox regression analysis for remission incidence during the 8-week treatment was conducted. Results: Between remitters and non-remitters, significant differences in genotype frequencies were observed in five of the investigated SLC6A2 variants (rs28386840, rs1532701, rs40434, rs13333066, rs187714). GCG haplotype (rs40434-rs13333066-rs187714) in the SLC6A2 gene showed a association with non-remission. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714). Conclusion: Our results suggest that the variation of the SLC6A2 gene is associated with treatment remission after venlafaxine in patients with MDD.

AB - Objective: Venlafaxine, an antidepressant of the serotonin-norepinephrine reuptake inhibitor (SNRI) type, is used to treat patients with major depressive disorder (MDD). Much evidence suggests that genetic polymorphisms may modulate serotonergic and noradrenergic function, thereby affecting the treatment efficacy of venlafaxine. The aim of this study was to examine whether polymorphisms in the norepinephrine transporter gene (SLC6A2) associate with remission after venlafaxine treatment for MDD. Method: An 8-week naturalistic treatment study with venlafaxine was carried out in 243 Han Chinese patients with MDD. The patients were screened for seven single-nucleotide polymorphisms of the SLC6A2 gene. Of the enrolled patients, 161 completed the 8-week treatment. The 21-item Hamilton Depression Rating Scale (HDRS) was used to assess the improvement of depressive symptoms in each subject from baseline to the endpoint. For better presentation of time-course change of remission status, a Cox regression analysis for remission incidence during the 8-week treatment was conducted. Results: Between remitters and non-remitters, significant differences in genotype frequencies were observed in five of the investigated SLC6A2 variants (rs28386840, rs1532701, rs40434, rs13333066, rs187714). GCG haplotype (rs40434-rs13333066-rs187714) in the SLC6A2 gene showed a association with non-remission. A Cox regression analysis for remission incidence during the 8-week treatment course significantly depends on SLC6A2 variants (rs28386840, rs40434, and rs187714). Conclusion: Our results suggest that the variation of the SLC6A2 gene is associated with treatment remission after venlafaxine in patients with MDD.

UR - http://www.scopus.com/inward/record.url?scp=84921611180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921611180&partnerID=8YFLogxK

U2 - 10.1016/j.jpsychires.2014.11.017

DO - 10.1016/j.jpsychires.2014.11.017

M3 - Article

C2 - 25512257

AN - SCOPUS:84921611180

VL - 61

SP - 33

EP - 39

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -